Abbott Plays On Diverse Offering As It Cruises Higher Than Most In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Size matters and Abbott Laboratories amply demonstrated its significance when last year it emerged as the dark horse and acquired the India prescriptions business of Piramal Healthcare Ltd. at a steep valuation of $3.72 billion, or 9 times the sales and 31 times the pre-tax profit
You may also be interested in...
Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two
Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies
Follow The CEO? Abbott Chief Chooses Diversified Products, Emerging Markets Over Rx Drugs As Company Splits In Two
Abbott Laboratories CEO Miles White has complained for a long time that U.S. investors don't understand the growth opportunity of emerging markets. Now White finally has a chance to put his money where his mouth is, choosing to lead a diversified medical products company rather than an innovative pharmaceutical company that will carry a different name, following a decision to split Abbott into two companies
Danone Gets Second Time Lucky, Buys Wockhardt's Nutrition Brands That Abbott Had Won And Lost
HYDERABAD, India - After several months of discussions, debt-laden Indian drug maker Wockhardt Ltd. finally managed to sell its growing nutritional business to French food giant Group Danone for reportedly $354 million - a quantum jump from the $130 million that Abbott Laboratories Ltd. had agreed to pay for the same assets exactly two years ago